Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 2,678 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 2,678 shares of Castle Biosciences stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $31.85, for a total value of $85,294.30. Following the transaction, the insider owned 53,615 shares of the company’s stock, valued at $1,707,637.75. The trade was a 4.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Castle Biosciences Stock Performance

Shares of NASDAQ CSTL traded down $0.02 during trading on Thursday, reaching $33.55. 678,649 shares of the company traded hands, compared to its average volume of 457,800. The firm’s fifty day simple moving average is $23.68 and its 200 day simple moving average is $20.26. The stock has a market cap of $979.29 million, a P/E ratio of -74.56 and a beta of 1.12. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $34.64. The company has a current ratio of 6.47, a quick ratio of 6.69 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. The business had revenue of $83.04 million during the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. Castle Biosciences has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after purchasing an additional 655 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Castle Biosciences by 1.0% during the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock worth $1,439,000 after purchasing an additional 707 shares in the last quarter. Diversify Wealth Management LLC lifted its stake in Castle Biosciences by 5.8% during the first quarter. Diversify Wealth Management LLC now owns 13,102 shares of the company’s stock worth $260,000 after purchasing an additional 717 shares in the last quarter. Inspire Investing LLC lifted its stake in Castle Biosciences by 4.0% during the third quarter. Inspire Investing LLC now owns 19,887 shares of the company’s stock worth $453,000 after purchasing an additional 770 shares in the last quarter. Finally, CWM LLC lifted its stake in Castle Biosciences by 80.6% during the third quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after purchasing an additional 853 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 30th. Canaccord Genuity Group restated a “buy” rating and issued a $37.00 price target on shares of Castle Biosciences in a research note on Tuesday, September 9th. Robert W. Baird lifted their price target on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, BTIG Research lifted their price target on Castle Biosciences from $32.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.43.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.